KRAS and colorectal carcinoma: Interestingly, the pre-amplification of starting cfDNA material targeting KRAS/NRAS exons 2, 3 and 4 by multiplex PCR in the OncoBEAM-TM-RAS-CRC assay did not increase the risk of obtaining a false-positive background.